公开(公告)号：US20210388085A1

公开(公告)日：2021-12-16

申请号：US17324148

申请日：2021-05-19

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Michael J. McCauley ,  Kristen Wiley ,  Rebecca Wissner

IPC: C07K16/28 ,  A61K47/68 ,  C12N9/10

Abstract: Engineered antibodies useful for site-specific conjugation by a transglutaminase are described. Also described are methods of site-specific conjugation of the antibodies, the site-specifically conjugated antibodies, and pharmaceutical compositions and uses related to the site-specifically conjugated antibodies.

公开(公告)号：US20210147510A1

公开(公告)日：2021-05-20

申请号：US16949078

申请日：2020-10-13

Applicant: Janssen Biotech, Inc.

Inventor： Rosa Cardoso ,  Michael Diem ,  Shalom Goldberg ,  Linus Hyun ,  Steven Jacobs ,  Donna Klein ,  Karyn O'Neil ,  Tracy Spinka-Doms

IPC: C07K14/78 ,  A61K51/08 ,  G01N33/574

Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

公开(公告)号：US20240384002A1

公开(公告)日：2024-11-21

申请号：US18792966

申请日：2024-08-02

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Michael J. McCauley ,  Kristen Wiley

IPC: C07K16/30 ,  A61K47/54 ,  A61K47/62 ,  A61K47/68 ,  C07K1/107

Abstract: Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.

公开(公告)号：US20160347840A1

公开(公告)日：2016-12-01

申请号：US15148371

申请日：2016-05-06

Applicant: Janssen Biotech, Inc.

Inventor： Glenn Anderson ,  Rosa Cardoso ,  Michael Diem ,  Francois Gaudet ,  Shalom Goldberg ,  Benjamin Harman ,  Linus Hyun ,  Steven Jacobs ,  Donna Klein ,  Yingzhe Li ,  Jinquan Luo ,  Ronan McDaid ,  Jill Mooney ,  Jennifer Nemeth-Seay ,  Karyn O'Neil ,  Steven Pomerantz ,  Galla Chandra Rao ,  Tracy Spinka-Doms ,  Alexey Teplyakov ,  Leopoldo Luistro ,  Sheng-Jiun Wu

IPC: C07K16/28 ,  C07K14/78 ,  A61K45/06 ,  C07K16/30 ,  A61K39/395

CPC classification number: C07K16/2809 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6869 ,  A61K49/0045 ,  A61K49/0058 ,  A61K2039/505 ,  C07K14/78 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2318/20 ,  C07K2319/30 ,  C12Y304/17021

Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.

Abstract translation: 本文提供了分离的CD3×PSMA-双特异性抗原结合分子或其双特异性抗原结合片段，其中FN3结构域特异性结合人前列腺特异性膜抗原（PSMA）和第二抗原结合位点免疫特异性结合CD3。 还描述了能够编码所提供的融合蛋白的融合蛋白和相关多核苷酸，以及表达所提供的融合蛋白的细胞。 此外，描述了使用所提供的分离的CD3×PSMA-双特异性抗原结合分子或其双特异性抗原结合片段的方法。

公开(公告)号：US20160326232A1

公开(公告)日：2016-11-10

申请号：US15148312

申请日：2016-05-06

Applicant: Janssen Biotech, Inc.

Inventor： Cardosa Rosa ,  Michael Diem ,  Shalom Goldberg ,  Linus Hyun ,  Steven Jacobs ,  Donna Klein ,  Karyn O'Neil ,  Tracy Spinka-Doms

IPC: C07K14/78 ,  G01N33/573 ,  A61K51/08

CPC classification number: C07K14/78 ,  A61K38/00 ,  A61K51/08 ,  G01N33/57434 ,  G01N2333/705

Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Abstract translation: PSMA结合FN3结构域，它们的缀合物，编码分子的分离的核苷酸，载体，宿主细胞及其制备方法可用于治疗分子的产生以及疾病和病症的治疗和诊断。

公开(公告)号：US20240391849A1

公开(公告)日：2024-11-28

申请号：US18736405

申请日：2024-06-06

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Joseph Erhardt ,  Rhys Salter ,  Theresa McDevitt

IPC: C07B59/00 ,  A61K39/00 ,  A61K51/10 ,  A61P35/00 ,  C07K16/30

Abstract: Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.

公开(公告)号：US20210017099A1

公开(公告)日：2021-01-21

申请号：US16955094

申请日：2018-12-17

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Joseph Erhardt ,  Rhys Salter ,  Theresa McDevitt

IPC: C07B59/00 ,  C07K16/30 ,  A61K51/10 ,  A61P35/00

Abstract: Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.

公开(公告)号：US10662235B2

公开(公告)日：2020-05-26

申请号：US15629090

申请日：2017-06-21

Applicant: Janssen Biotech, Inc.

Inventor： Mark Anderson ,  Ricardo Attar ,  Michael Diem ,  Linus Hyun ,  Alastair King ,  Steven Jacobs ,  Shalom Goldberg ,  Donna Klein ,  Sheri Moores ,  Karyn O'Neil ,  Kristen Picha

IPC: C07K14/71 ,  C07K14/78 ,  C07K19/00 ,  C12N15/09 ,  C12N15/12 ,  C12N15/63 ,  C12N15/64

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

公开(公告)号：US10196446B2

公开(公告)日：2019-02-05

申请号：US14512801

申请日：2014-10-13

Applicant: Janssen Biotech, Inc.

Inventor： Shalom Goldberg ,  Steven Jacobs ,  Tricia Lin ,  Karyn O'Neil

IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78 ,  A61K39/00

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

公开(公告)号：US20150104808A1

公开(公告)日：2015-04-16

申请号：US14512801

申请日：2014-10-13

Applicant: JANSSEN BIOTECH, INC.

Inventor： Shalom Goldberg ,  Steven Jacobs ,  Tricia Lin

IPC: C07K16/28 ,  G01N33/74 ,  C07K14/435

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K14/78 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  G01N33/74

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Abstract translation: 通过诱变母体分子的核酸序列并用半胱氨酸代替一个或多个氨基酸残基来编码半胱氨酸来制备含有一个或多个游离半胱氨酸氨基酸的半胱氨酸改造的单特异性和双特异性EGFR和/或c-Met FN3结构域的分子， 设计的含有单特异性或双特异性分子的FN3结构域; 表达含有半胱氨酸的FN3结构域的分子; 并回收含有半胱氨酸的FN3结构域的分子。 分离的半胱氨酸改造的单特异性或双特异性FN3结构域含有的分子可以共价连接到检测标记或药物部分，并在治疗上使用。